Skip to main content

Advertisement

ADVERTISEMENT

Nonradiographic Axial Spondyloarthritis News

News
10/14/2022
Study authors compared early vs late symptom duration and the efficacy of secukinumab in younger vs older patients with nonradiographic axial spondyloarthritis.
Study authors compared early vs late symptom duration and the efficacy of secukinumab in younger vs older patients with nonradiographic axial spondyloarthritis.
Study authors compared early vs...
10/14/2022
First Report Managed Care
News
09/29/2022
Researchers assessed the frequency and anatomic distribution of lesions in the sacroiliac joint via MRI among patients with and without spondyloarthritis.
Researchers assessed the frequency and anatomic distribution of lesions in the sacroiliac joint via MRI among patients with and without spondyloarthritis.
Researchers assessed the...
09/29/2022
First Report Managed Care

Advertisement

News
08/26/2022
Researchers determined questionnaires were reliable for assessing quality of life concerns among patients with nonradiographic axial spondyloarthritis.
Researchers determined questionnaires were reliable for assessing quality of life concerns among patients with nonradiographic axial spondyloarthritis.
Researchers determined...
08/26/2022
First Report Managed Care
News
06/30/2022
Findings showed women with nonradiographic axial spondyloarthritis (nraxSpA) had a lower average polygenic risk score and lower HLA-B27 prevalence when compared to men with nraxSpA. 
Findings showed women with nonradiographic axial spondyloarthritis (nraxSpA) had a lower average polygenic risk score and lower HLA-B27 prevalence when compared to men with nraxSpA. 
Findings showed women with...
06/30/2022
First Report Managed Care
News
06/20/2022
“This study demonstrated that secukinumab can be a viable option to treat the entire spectrum of axial spondyloarthritis (axSpA), that is, from early to late stage or from nonradiographic axSpA to radiographic axSpA,” wrote researchers.
“This study demonstrated that secukinumab can be a viable option to treat the entire spectrum of axial spondyloarthritis (axSpA), that is, from early to late stage or from nonradiographic axSpA to radiographic axSpA,” wrote researchers.
“This study demonstrated that...
06/20/2022
First Report Managed Care

Advertisement

News
05/26/2022
Researchers determined the effects of a short course of etanercept on disease activity, the chance of biological treatment, or radiographic progression in patients with nonradiographic axial spondyloarthritis. 
Researchers determined the effects of a short course of etanercept on disease activity, the chance of biological treatment, or radiographic progression in patients with nonradiographic axial spondyloarthritis. 
Researchers determined the...
05/26/2022
First Report Managed Care
News
04/14/2022
A recent analysis explores nonradiographic axial spondyloarthritis as it relates to the overall axial spondyloarthritis spectrum and evaluates mimics of the disease.
A recent analysis explores nonradiographic axial spondyloarthritis as it relates to the overall axial spondyloarthritis spectrum and evaluates mimics of the disease.
A recent analysis explores...
04/14/2022
First Report Managed Care
News
03/31/2022
Study authors assessed the clinical outcomes of certolizumab pegol treatment in patients with active nonradiographic axial spondyloarthritis.
Study authors assessed the clinical outcomes of certolizumab pegol treatment in patients with active nonradiographic axial spondyloarthritis.
Study authors assessed the...
03/31/2022
First Report Managed Care

Advertisement

News
03/18/2022
Using patient age and symptom duration, researchers determined the appropriateness of X-ray vs MRI for the diagnosis of radiographic and nonradiographic axial spondyloarthritis.
Using patient age and symptom duration, researchers determined the appropriateness of X-ray vs MRI for the diagnosis of radiographic and nonradiographic axial spondyloarthritis.
Using patient age and symptom...
03/18/2022
First Report Managed Care
News
10/15/2021
“The highest treatment differences between secukinumab and placebo were observed in patients with both elevated [C-reactive protein levels] and evidence of sacroiliitis on MRI,” researchers wrote.
“The highest treatment differences between secukinumab and placebo were observed in patients with both elevated [C-reactive protein levels] and evidence of sacroiliitis on MRI,” researchers wrote.
“The highest treatment...
10/15/2021
First Report Managed Care

Advertisement